Skip to main content

Table 2 Summarize of pretreatment NLR in each prostate cancer status

From: A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment

Treatment

n

Journal

Pre and post DOC treatment

449

Current Study

Pre CBZ treatment

47

Uemura and Kawahara et al. Biomed Res Int. 2017

Initial metastatic prostate cancer

48

Kawahara and Yokomizo et al. BMC Cancer 2016

PSA 4 to 10 ng/mL

810

Kawahara and Fukui et al. Oncotarget 2015

  1. DOC Docetaxel, CBZ Cabazitaxel, PSA Prostate-specific antigen